ESR1 and breast carcinoma: However, the prognostic impact of HER2 in breast cancer and the effectiveness of its drug target are well established in breast cancer patients, whereas the role of other protein tyrosine kinases (PTKs) in the loop of networks in ER+ breast cancer patients is rather unknown.